142
Participants
Start Date
September 26, 2024
Primary Completion Date
February 28, 2027
Study Completion Date
July 31, 2029
Olvimulogene nanivacirepvec
Olvi-Vec is an engineered oncolytic vaccinia virus
Platinum chemotherapy: carboplatin or cisplatin
Administered according to local practice.
Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
Administered according to local practice.
Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab
Administered according to local practice.
Docetaxel
Administered according to local practice.
RECRUITING
University of Maryland Medical Center Greenebaum Comprehensive Cancer Center, Baltimore
RECRUITING
Mid Florida Hematology and Oncology Center, Orange City
RECRUITING
Bioresearch Partner, Hialeah
RECRUITING
Oncology & Hematology Associates of West Broward, Coral Springs
RECRUITING
University of Miami - Sylvester Comprehensive Cancer Center, Miami
RECRUITING
Bioresearch Partner, Miami
RECRUITING
Helios Clinical Research, Fort Lauderdale
RECRUITING
BRCR Medical Center, Inc., Plantation
RECRUITING
Clermont Oncology Center, Clermont
RECRUITING
Gabrail Cancer and Research Center, Canton
RECRUITING
Michigan Hematology and Oncology Consultants, Dearborn
RECRUITING
Oakland Medical Group, Farmington Hills
RECRUITING
Sheboygan Cancer & Blood Center, Sheboygan
RECRUITING
World Research Link, Baytown
RECRUITING
Texas Oncology - Austin Central, Austin
RECRUITING
Pioneer Research Center, LLC, Bullhead City
Lead Sponsor
Newsoara Biopharma Co., Ltd.
INDUSTRY
Genelux Corporation
INDUSTRY